[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Thrombolex, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100549361","the-rapid---pe-study-rescue-advanced-protocol-for-the-treatment-of-pulmonary-embolism-100549361",false,"NCT06433011","The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism","The RAPID - PE Study: RESCUE Advanced Protocol Without ICU Stay and no Lytic Drip - for the Treatment of Pulmonary Embolism","Inclusion Criteria\n\n1. Willing and able to provide informed consent;\n2. PE symptom duration ≤ 15 days;\n3. Filling defect in at least one major lobar pulmonary artery as determined by CTA;\n4. Patient is diagnosed with intermediate risk PE;\n5. RV\u002FLV diameter ratio ≥ 0.9 by CTA, as determined by investigative site;\n6. Willing and able to comply with all study procedures and 7-day and 30-day telephone follow-up visit.\n\nExclusion Criteria:\n\n1. Previous history of stroke with residual hemiplegia;\n2. Major surgery ≤ 10 days prior to inclusion in the study;\n3. Platelet count \\\u003C 100,000\u002FμL;\n4. Pulmonary thrombectomy within the previous 4 days;\n5. Uncontrolled hypertension defined as systolic blood pressure \\>180 mm Hg and\u002For diastolic blood pressure \\>110 mm Hg at the time of the procedure;\n6. Administration of thrombolytic agents within the previous 4 days;\n7. Absolute contraindication to anticoagulation;\n8. Clinician deems high-risk for catastrophic bleeding;\n9. Pregnancy;\n10. Any vasopressor or inotropic support;\n11. Cardiac arrest (including pulseless electrical activity (PEA) and asystole) requiring active cardiopulmonary resuscitation (CPR) during this hospitalization at treating institution and\u002For referring institution;\n12. Planning to administer r-tPA by infusion after the r-tPA is administered by pulse sprays;\n13. Currently participating in another study;\n14. In the opinion of the investigator, the subject is not a suitable candidate for the study.","ALL",{"count":18,"type":19},500,"ESTIMATED","INTERVENTIONAL",[22],"NA","To demonstrate the efficacy and safety of the 8F BASHIR™ .035 Endovascular Catheter and the 8F BASHIR™ S-B .035 Endovascular Catheter for the administration of pharmaco-mechanical catheter directed therapy using pulse sprays of r-tPA into the pulmonary arteries for the treatment of intermediate risk pulmonary embolism (PE).",[25],"Pulmonary Embolism",[25,27],"Catheter Directed Therapy","RECRUITING","2026-07-13",{"date":31,"type":32},"2026-07-14","ACTUAL",{"date":34,"type":32},"2024-10-17",{"date":36,"type":19},"2028-04-25",{"name":38,"class":39},"Thrombolex, Inc.","INDUSTRY",23,""]